SEC Form SC 13D/A filed by Mallinckrodt plc (Amendment)
$MNK
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net Sales of $424.6 Million; Net Loss of $249.3 Million; Adjusted EBITDA of $123.5 Million; Diluted Loss Per Share of $18.93 and Adjusted Diluted Earnings Per Share of $1.68 Increased Cash on Hand to $480.0 Million and Reduced Exposure to Interest Rate Volatility Through Interest Rate Cap Agreement, Demonstrating Ongoing Focus on Disciplined Balance Sheet Management Reaffirmed 2023 Net Sales and Adjusted EBITDA Guidance Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, May 9, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Malli
DUBLIN, April 24, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that it will report first quarter 2023 earnings results for the period ended March 31, 2023, on Tuesday, May 9, 2023. A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows: Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BIbe1f9805fe5b4490acd8359f7bdd616dAudio Only Webcast Link (live and replay):https://edge.media-server.com/mmc/p/24fqexpxAt the Mallinckrodt website
Made Solid Progress on Launch of Terlivaz® with Significant Medical Community Interest Appointed Chief Scientific Officer with Proven Record of Executing Clinical Programs and Advancing Product Development Pipelines Increased Cash on Hand to $409.5 Million, Underscoring Commitment to Strengthening Balance Sheet and Disciplined Approach to Cost Management Fiscal 2023 Guidance for Adjusted EBITDA is $510 Million to $560 Million Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, Feb. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the fourth quarter ended December 30, 2022.
Continuing to Serve Customers and Deliver High-Quality Therapies to Patients Without Interruption; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023. As expected, the Court granted Mallinckrodt approval to ac
Initiates Voluntary Prepackaged Chapter 11 Proceedings with Overwhelming Support of Key Stakeholders, Including 85%+ of First and Second Lien Debtholders Continuing to Operate Normally, Serve Customers and Deliver High-Quality Therapies to Patients Vendors and Suppliers Expected to be Paid in Full in the Ordinary Course DUBLIN, Aug. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has taken the next step to implement the comprehensive financial restructuring plan contemplated by a Restructuring Support Agreement ("RSA") the Company previously entered into with more than 85% of each of th
Agreement Supported by a Substantial Majority of Each of its First and Second Lien Debtholders and Opioid Trust Financial Restructuring Plan to Significantly Reduce Debt, Increase Free Cash Flow Generation, Extend Maturity Runway and Better Position Company for Long-Term Success Intends to Initiate Voluntary Prepackaged Chapter 11 Proceedings to Implement Plan Continuing to Deliver High-Quality Therapies to Patients and Serve Customers; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 23, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced it has entered into a Restructur
SC 13D/A - Mallinckrodt plc (0001567892) (Subject)
SC 13D/A - Mallinckrodt plc (0001567892) (Subject)
SC 13D/A - Mallinckrodt plc (0001567892) (Subject)
DUBLIN, Jan. 12, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr. Peter Richardson, B.Med.Sci., BM, BS, MRCP (UK) has been appointed Executive Vice President and Chief Scientific Officer, effective January 12, 2023. With more than 30 years of research and development experience in the pharmaceutical industry, Dr. Richardson will have executive responsibility for Mallinckrodt's branded research and development (R&D), medical affairs, safety, and regulatory affairs functions. He will serve on the Company's Executive Committee and succeeds Steven Romano, M.D., who departed Mallinckrodt in Dece
4 - Mallinckrodt plc (0001567892) (Issuer)
4 - Mallinckrodt plc (0001567892) (Issuer)
4 - Mallinckrodt plc (0001567892) (Issuer)
8-K - Mallinckrodt plc (0001567892) (Filer)
8-K - Mallinckrodt plc (0001567892) (Filer)
10-Q - Mallinckrodt plc (0001567892) (Filer)
Mallinckrodt plc (OTC:MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023. As expected, the Court granted Mallinckrodt approval to access $150 million of the $250 million of commitments for new financing it received from certain of its creditors, as well as new borrowing availability from lenders under its asset-based loans. The approvals granted by the Court also enable the Company to continue paying employee wages, salaries and benefits without
Reuters Walmart Settles Lawsuit Regarding Allegations Of Light-Bulb Patent Infringement Walmart Inc (NYSE:WMT) has reportedly resolved the University of California's light-bulb patent lawsuit. The university accused the retail behemoth of infringing its patents associated with "filament" LED light bulbs (invented at the Santa Barbara-based school system). The federal judge in Los Angeles would dismiss the case with prejudice, which means it cannot be refiled. Renault Eyes Spring 2024 IPO For EV Unit Ampere Renault SA (OTC:RNLSY) (OTC:RNSDF) is reportedly expecting to list its electric vehicle business unit, Ampere, on the stock market in the spring of 2024. Renault Chief Executiv